# Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

> **NCT00628810** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 86 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** fluorouracil
- **DRUG:** irinotecan hydrochloride
- **DRUG:** leucovorin calcium

## Key facts

- **NCT ID:** NCT00628810
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-12
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628810, "Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00628810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*